Laura J. van 't Veer
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
van t Veer L 2024 Impact Report
Open Date: 2024-03-26
Close Date: 2024-03-26
Grant: Close
Treatment-induced Changes in Molecular and Pathway Dynamics as Determinants of Non-Response
Open Date: 2022-10-01
Close Date: 2023-09-30
Articles (51)
Year:
2026
Purpose: Pretreatment specimens from patients treated on the I-SPY2 neoadjuvant breast cancer trial were studied to identify prespecified biomarkers associated with response to the regimen of paclitaxel, the anti–type I insulin-like growth factor receptor (IGF-1R) antibody ganitumab, and metformin (PGM) followed by doxorubicin and cyclophosphamide (AC) compared with control therapy (paclitaxel followed by AC). The primary endpoint of this trial is pathologic complete response (pCR). Experimental Design: One hundred six patients treated with PGM and 119 contemporary controls were evaluated using laser capture microdissection and reverse-phase protein array to evaluate 32 prespecified potential predictive biomarkers in the IGF-1R pathway and 109 additional exploratory endpoints. Results: Total levels of IGF-1R were poorly correlated with phosphorylated IGF-1R/insulin receptor (IR). Higher levels of phosphorylated IGF-1R/IR were associated with an increased likelihood of obtaining pCR, especially in the hormone receptor (HR)–positive subgroup. Markers of immune response also showed an association with pCR but differed between HR+ and HR− subgroups. In HR− tumors, phospho-STAT1 Y701 and low levels of phospho-p27 associated with pCR. These relationships were not observed in patients treated with control chemotherapy. Conclusions: Activation status of IGF-1R/IR associated with increased pCR to PGM in HR+ breast cancers. Immune activation markers were also associated with response in HR+ and HR− subgroups. Thus, IGF-1R may directly regulate tumor biology and associate with immune response to therapy.
Year:
2025
This study investigates the association between peripheral blood immunological features and immunotherapy response in breast cancer. We generated and analyzed RNAseq data from 546 blood samples of patients with high-risk stage II/III HER2-negative breast cancer enrolled in the I-SPY2 trial and identified peripheral immune signatures associated with tumor characteristics and immunotherapy response. Triple negative breast cancer (TNBC) patients showed higher T cell receptor (TCR) clonality and immune activation signatures. Responders to the chemotherapy + pembrolizumab regimen had high baseline TCR diversity, with TNBC responders experiencing T cell clonal expansion and activation after treatment. A logistic regression model based on immunological features before and early-on-treatment predicted response to pembrolizumab. The model was validated in an independent cohort of patients treated with dostarlimab in the neoadjuvant setting. We report the potential of peripheral blood-derived gene expression tests to predict immunotherapy benefit, guiding personalized treatment in breast cancer with a minimally invasive approach.
Year:
2025
Purpose: The MammaPrint (MP) prognostic assay categorizes breast cancers into high- and low-risk subgroups, and the high-risk group can be further subdivided into high-1 (MP-H1), and very high-risk high-2 (MP-H2). The aim of this analysis was to assess clinical and molecular differences between the hormone receptor–positive (HR + )/HER2-negative MP-H1, -H2, and triple-negative (TN) MP-H1 and -H2 cancers. Experimental Design: Pretreatment gene expression data from 742 HER2-negative breast cancers enrolled in the I-SPY2 neoadjuvant trial were used. Prognostic risk categories were assigned using the MP assay. Transcriptional similarities across the four receptor and prognostic groups were assessed using principal component analyses and by identifying differentially expressed genes. We also examined pathologic complete response rates and event-free survivals by risk group. Results: Principal component analysis showed that HR +/ MP-H2 tumors clustered with TN/MP-H2 cancers. Only 125 genes showed differential expression between the HR +/ MP-H2 and TN/MP-H2 cancers, whereas 1,465 genes were differentially expressed between HR +/ MP-H2 and -H1. Gene set analysis revealed similarly high expression of cell cycle, DNA repair, and immune infiltration–related pathways in HR +/ MP-H2 and TN/MP-H2 cancers. HR +/ MP-H2 cancers also showed low estrogen receptor–related gene expression. Pathologic complete response rates were similarly high in TN/MP-H2 and HR +/ MP-H2 cancers (42% vs. 30.5%; P = 0.11), and MP-H2 cancers with residual cancer had similarly poor event-free survival regardless of estrogen receptor status. Conclusions: In conclusion, HR +/ MP-H2 cancers closely resemble TN breast cancers in transcriptional and clinical features and benefit from similar treatment strategies.
Year:
2025
Purpose: We previously demonstrated the clinical significance of circulating tumor DNA (ctDNA) in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy (NAC). Here, we compared its predictive and prognostic value with cell-free DNA (cfDNA) concentration measured in the same samples from the same patients. Experimental Design: 145 patients with hormone receptor (HR)-positive/HER2-negative and 138 triple-negative breast cancer (TNBC) with ctDNA data from a previous study were included in the analysis. Associations of serial cfDNA concentration with residual cancer burden (RCB) and distant recurrence-free survival (DRFS) were examined. Results: In TNBC, we observed a modest negative correlation between cfDNA concentration 3 weeks after treatment initiation and RCB, but none of the other timepoints showed significant correlation. In contrast, ctDNA was significantly positively correlated with RCB at all timepoints (all R > 0.3 and P < 0.05). In the HR-positive/HER2-negative group, cfDNA concentration did not associate with response to NAC, but survival analysis showed that high cfDNA shedders at pretreatment had a significantly worse DRFS than low shedders (hazard ratio, 2.12; P = 0.037). In TNBC, the difference in survival between high versus low cfDNA shedders at all timepoints was not statistically significant. In contrast, as previously reported, ctDNA at all timepoints was significantly correlated with DRFS in both subtypes. Conclusions: In TNBC, cfDNA concentrations during therapy were not strongly correlated with response or prognosis. In the HR-positive/HER2-negative group, pretreatment cfDNA concentration was prognostic for DRFS. Overall, the predictive and prognostic value of cfDNA concentration was more limited than that of ctDNA.
Year:
2024
Despite efforts to understand breast cancer biology, metastatic disease remains a clinical challenge. Identifying suppressors of breast cancer progression and mechanisms of transition to more invasive phenotypes could provide game changing therapeutic opportunities. Transcriptional deregulation is central to all malignancies, highlighted by the extensive reprogramming of regulatory elements that underlie oncogenic programs. Among these, super-enhancers (SEs) stand out due to their enrichment in genes controlling cancer hallmarks. To reveal novel breast cancer dependencies, we integrated the analysis of the SE landscape with master regulator activity inference for a series of breast cancer cell lines. As a result, we identified T - h elper-inducing Poxviruses and Zinc-finger ( PO Z)/ K rüppel-like factor (ThPOK, ZBTB7B ), a CD4 + cell lineage commitment factor, as a breast cancer master regulator that is recurrently associated with a SE. ThPOK expression is highest in luminal breast cancer but is significantly reduced in the basal subtype. Manipulation of ThPOK levels in cell lines shows that its repressive function restricts breast cancer cells to an epithelial phenotype by suppressing the expression of genes involved in the epithelial-mesenchymal transition (EMT), WNT/β-catenin target genes, and the pro-metastatic TGFβ pathway. Our study reveals ThPOK as a master transcription factor that restricts the acquisition of metastatic features in breast cancer cells.
Year:
2024
Survival curves of patients stratified into two groups, cfDNA high shedders vs. cfDNA low shedders. CfDNA concentration was measured in the plasma of patients with A. hormone receptor-positive HER2-negative (HR+HER2-) and B. triple-negative breast cancer (TNBC). The median cfDNA concentration was used as the cutoff to stratify patients into high vs. low cfDNA-shedders. The survival endpoint was distant recurrence-free survival (DRFS). P values were calculated using the Wald test. Blood was collected at pretreatment (T0), 3 weeks after treatment initiation (T1), 12 weeks after treatment initiation between paclitaxel-based treatment and anthracycline regimens (T2), and after neoadjuvant chemotherapy before surgery (T3).
Year:
2024
Survival curves of patients stratified into two groups, cfDNA high shedders vs. cfDNA low shedders. CfDNA concentration was measured in the plasma of patients with A. hormone receptor-positive HER2-negative (HR+HER2-) and B. triple-negative breast cancer (TNBC). The median cfDNA concentration was used as the cutoff to stratify patients into high vs. low cfDNA-shedders. The survival endpoint was distant recurrence-free survival (DRFS). P values were calculated using the Wald test. Blood was collected at pretreatment (T0), 3 weeks after treatment initiation (T1), 12 weeks after treatment initiation between paclitaxel-based treatment and anthracycline regimens (T2), and after neoadjuvant chemotherapy before surgery (T3).
Year:
2024
Association between cfDNA concentration and residual cancer burden (RCB). CfDNA concentration was measured in the plasma of patients with A. hormone receptor-positive HER2-negative (HR+HER2-) and B. triple-negative breast cancer (TNBC). Blood was collected at pretreatment (T0), 3 weeks after treatment initiation (T1), 12 weeks after treatment initiation between paclitaxel-based treatment and anthracycline regimens (T2), and after neoadjuvant chemotherapy (NAC) before surgery (T3). RCB was divided into 4 classes: RCB-0, equivalent to pathologic complete response, and RCB-I, -II, -III, representing limited, moderate, and extensive residual cancer after NAC, respectively. Pairwise P values were calculated using the Wilcoxon rank sum test, with Bonferroni correction to adjust for multiple comparisons.
Year:
2024
Association between pretreatment cfDNA concentration and clinicopathologic variables. CfDNA concentration was measured in pretreatment plasma of patients with A. hormone receptor-positive HER2-negative (HR+HER2-) and B. triple-negative breast cancers (TNBC). P values were calculated using the Wilcoxon rank sum test.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (43)
Nola Hylton
Professor
University of California, San Francisco
Lajos Pusztai
Yale University
Michelle Melisko
Clinical Professor of Medicine
University of California, San Francisco
Vijaya Bharti
Research assistant professor
Vanderbilt University
Paola Betancur
Assistant Professor
University of California, San Francisco
Amy Clark
Assistant Professor of Medicine
University of Pennsylvania
Isabel T Rubio
Clinica Universidad de Navarra
Amy Jo Chien
Professor of Clinical Medicine Medical Director, Breast Oncology
University of California, San Francisco
Sarah Blair
Professor
UC San Diego Health System
Angela DeMichele
University of Pennsylvania
Justin M. Balko
Vanderbilt University Medical Center
Mary Helen Barcellos-Hoff
Professor/Vice Chair
University of California, San Francisco
W. Fraser Symmans
Professor
The University of Texas MD Anderson Cancer Center
brian lehmann
Research Assistant Professor
Vanderbilt University Medical Center
Paula Pohlmann
The University of Texas MD Anderson Cancer Center
Payal D. Shah
University of Pennsylvania
Kathy Albain
Professor of Medicine
Loyola University Chicago Stritch School of Medicine
Julie E. Lang
University of Southern California
Xiaopeng Sun
Vanderbilt University
Rita Nanda
Associate Professor of Medicine; Director Breast Oncology
University of Chicago
Hope Rugo
Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology
City Of Hope National Medical Center
Yunn-Yi Chen
Professor
UCSF Medical Center
Erica M. Stringer-Reasor
Associate Professor
The University of Alabama
Tarah Ballinger
Associate Professor of Medicine
Indiana University School of Medicine
Rolando Garcia-Milian
Lecturer in Epidemiology
Yale School of Public Health
Gillian Hirst
Associate Professor
University of California, San Francisco
Rosa Isela Gallagher
Senior Research Scientist
George Mason University
Cesar Santa-Maria
Associate Professor
Johns Hopkins University
Andres Ocampo
Vanderbilt University
Michal Marczyk
Adjunct Assistant Professor
Yale University School of Medicine
Juliana Bronzini
Vanderbilt University
Wen Li
Associate Specialist
University of California, San Francisco
Minetta Liu
Research Collaborator, Professor
Mayo Clinic
Douglas Yee
Professor
University of Minnesota
Laura Esserman
University of California
Claudine Isaacs
Professor of Medicine
Georgetown University
LAMORNA SWIGART
University of California, San Francisco
John T. Wilson
Vanderbilt University
Vandana Abramson
Professor of Medicine
-
Yaomin Xu
Associate Professor
University of Texas Southwestern Medical Center
David Potter
Associate Professor
University of Minnesota
Rosalyn Sayaman
Assistant Adjunct Professor
University of California, San Francisco
Julie Saba
Professor
University of California, San Francisco
Make your next move.
Prepare your application
Review drafts before you send them.